Matthew J Barrett1, Mark E Smolkin2, Joseph L Flanigan3, Binit B Shah4, Madaline B Harrison5, Scott A Sperling6. 1. Department of Neurology, University of Virginia, Charlottesville, VA, USA. Electronic address: mjbarrett@virginia.edu. 2. Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA. Electronic address: mes6r@virginia.edu. 3. Department of Neurology, University of Virginia, Charlottesville, VA, USA. Electronic address: jlf4m@virginia.edu. 4. Department of Neurology, University of Virginia, Charlottesville, VA, USA. Electronic address: bbs7s@virginia.edu. 5. Department of Neurology, University of Virginia, Charlottesville, VA, USA. Electronic address: mbh3y@virginia.edu. 6. Department of Neurology, University of Virginia, Charlottesville, VA, USA. Electronic address: sas7yr@virginia.edu.
Abstract
INTRODUCTION: Considering that psychosis in Parkinson disease (PD) is associated with worse outcomes, including dementia, we aimed to study the characteristics, correlates, and assessment of PD psychosis in those without dementia. METHODS: 101 PD subjects without dementia (Montreal Cognitive Assessment ≥21/30) were recruited to participate in a study of neuropsychiatric symptoms in PD. This study included a baseline standard neurological exam and common PD symptom assessments. Using the Scale for the Assessment of Positive Symptoms (SAPS) and separate assessment of visual illusions and sense of presence, NINDS-NIMH criteria for PD psychosis were applied. RESULTS: Of the 33 (32.7%) PD subjects who met diagnostic criteria for psychosis in PD, visual illusions were most common (72.7%), followed by visual hallucinations (39.4%). Adjusted for presence of REM sleep behavior disorder (RBD) (p = 0.097), use of dopamine agonists (OR = 3.7, p = 0.012) and greater autonomic symptom burden (OR = 1.1 (per 1-unit change in score on SCOPA-AUT), p = 0.012) were associated with greater risk of psychosis. Use of dopamine agonists (OR = 5.0, p = 0.007), higher MDS-UPDRS Part II score (OR = 1.1, p = 0.010), and presence of RBD (OR = 4.8, p = 0.012) were independent predictors of visual hallucinations and visual illusions. MDS-UPDRS item 1.2 score ≥1 had highly correlated with the SAPS score (r = 0.65, p < 0.0001), but was 42% sensitive and 96% specific for identifying psychosis. CONCLUSION: This study confirms the association between dopamine agonists and psychosis in PD patients without dementia. The association of RBD, autonomic symptoms, and MDS-UPDRS Part II scores with psychosis underscore its link to brainstem dysfunction and greater PD motor symptom severity.
INTRODUCTION: Considering that psychosis in Parkinson disease (PD) is associated with worse outcomes, including dementia, we aimed to study the characteristics, correlates, and assessment of PD psychosis in those without dementia. METHODS: 101 PD subjects without dementia (Montreal Cognitive Assessment ≥21/30) were recruited to participate in a study of neuropsychiatric symptoms in PD. This study included a baseline standard neurological exam and common PD symptom assessments. Using the Scale for the Assessment of Positive Symptoms (SAPS) and separate assessment of visual illusions and sense of presence, NINDS-NIMH criteria for PD psychosis were applied. RESULTS: Of the 33 (32.7%) PD subjects who met diagnostic criteria for psychosis in PD, visual illusions were most common (72.7%), followed by visual hallucinations (39.4%). Adjusted for presence of REM sleep behavior disorder (RBD) (p = 0.097), use of dopamine agonists (OR = 3.7, p = 0.012) and greater autonomic symptom burden (OR = 1.1 (per 1-unit change in score on SCOPA-AUT), p = 0.012) were associated with greater risk of psychosis. Use of dopamine agonists (OR = 5.0, p = 0.007), higher MDS-UPDRS Part II score (OR = 1.1, p = 0.010), and presence of RBD (OR = 4.8, p = 0.012) were independent predictors of visual hallucinations and visual illusions. MDS-UPDRS item 1.2 score ≥1 had highly correlated with the SAPS score (r = 0.65, p < 0.0001), but was 42% sensitive and 96% specific for identifying psychosis. CONCLUSION: This study confirms the association between dopamine agonists and psychosis in PDpatients without dementia. The association of RBD, autonomic symptoms, and MDS-UPDRS Part II scores with psychosis underscore its link to brainstem dysfunction and greater PD motor symptom severity.
Authors: Natalie Ellis; Amelia Tee; Branduff McAllister; Thomas Massey; Duncan McLauchlan; Timothy Stone; Kevin Correia; Jacob Loupe; Kyung-Hee Kim; Douglas Barker; Eun Pyo Hong; Michael J Chao; Jeffrey D Long; Diane Lucente; Jean Paul G Vonsattel; Ricardo Mouro Pinto; Kawther Abu Elneel; Eliana Marisa Ramos; Jayalakshmi Srinidhi Mysore; Tammy Gillis; Vanessa C Wheeler; Christopher Medway; Lynsey Hall; Seung Kwak; Cristina Sampaio; Marc Ciosi; Alastair Maxwell; Afroditi Chatzi; Darren G Monckton; Michael Orth; G Bernhard Landwehrmeyer; Jane S Paulsen; Ira Shoulson; Richard H Myers; Erik van Duijn; Hugh Rickards; Marcy E MacDonald; Jong-Min Lee; James F Gusella; Lesley Jones; Peter Holmans Journal: Biol Psychiatry Date: 2019-12-17 Impact factor: 12.810